Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences arcus revenue from Gilead — License & development services (legacy axis, $M) ($M)
Arcus Biosciences (RCUS) Form 10-Q / 10-K
Latest, FY2025
214
Period ended Dec 31, 2025
Change on a year earlier
+3.4%
207 in FY2024
History
3 years
Since FY2023
Sources
1
Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus revenue from Gilead — License & development services (legacy axis, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 214 | +3.4% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2024 | Dec 31, 2024 | 207 | +176.0% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| FY2023 | Dec 31, 2023 | 75 | – | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus revenue from Gilead — License & development services (legacy axis, $M) ($M), annual FY2023–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_rev_gilead_lic
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.